Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13).

Weis J, Arraras JI, Conroy T, Efficace F, Fleissner C, Görög A, Hammerlid E, Holzner B, Jones L, Lanceley A, Singer S, Wirtz M, Flechtner H, Bottomley A.

Psychooncology. 2013 May;22(5):1002-7. doi: 10.1002/pon.3092. Epub 2012 May 4.

PMID:
22565359
2.

Absence of intestinal microbiota does not protect mice from diet-induced obesity.

Fleissner CK, Huebel N, Abd El-Bary MM, Loh G, Klaus S, Blaut M.

Br J Nutr. 2010 Sep;104(6):919-29. doi: 10.1017/S0007114510001303. Epub 2010 May 5.

PMID:
20441670
3.

Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy.

Kleeberg L, Morgera S, Jakob C, Hocher B, Schneider M, Peters H, Rötzer S, Müller C, Kaiser M, Fleissner C, Heider U, Neumayer HH, Sezer O.

Eur J Med Res. 2009;14:47-54.

4.

Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase.

von Metzler I, Krebbel H, Kuckelkorn U, Heider U, Jakob C, Kaiser M, Fleissner C, Terpos E, Sezer O.

J Cancer Res Clin Oncol. 2009 Feb;135(2):173-9. doi: 10.1007/s00432-008-0461-8. Epub 2008 Sep 3.

PMID:
18766375
5.

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.

Jakob C, Sterz J, Liebisch P, Mieth M, Rademacher J, Goerke A, Heider U, Fleissner C, Kaiser M, von Metzler I, Müller C, Sezer O.

Leukemia. 2008 Sep;22(9):1767-72. doi: 10.1038/leu.2008.159. Epub 2008 Jun 26. Erratum in: Leukemia. 2008 Sep;22(9):1812.

PMID:
18580957
6.

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

Kaiser M, Mieth M, Liebisch P, Oberländer R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U.

Eur J Haematol. 2008 Jun;80(6):490-4. doi: 10.1111/j.1600-0609.2008.01065.x. Epub 2008 Mar 10.

PMID:
18331598
7.

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.

Eur J Haematol. 2008 Feb;80(2):133-42. Epub 2007 Dec 20.

PMID:
18005386
8.

Molecular and clinical aspects of proteasome inhibition in the treatment of cancer.

Zavrski I, Jakob C, Kaiser M, Fleissner C, Heider U, Sezer O.

Recent Results Cancer Res. 2007;176:165-76. Review.

PMID:
17607924
9.

Bortezomib inhibits human osteoclastogenesis.

von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, Kaiser M, Jakob C, Sterz J, Kleeberg L, Heider U, Sezer O.

Leukemia. 2007 Sep;21(9):2025-34. Epub 2007 Jun 21.

PMID:
17581612
10.

Assessing quality of life in patients with colorectal cancer: an update of the EORTC quality of life questionnaire.

Gujral S, Conroy T, Fleissner C, Sezer O, King PM, Avery KN, Sylvester P, Koller M, Sprangers MA, Blazeby JM; European Organisation for Research and Treatment of Cancer Quality of Life Group.

Eur J Cancer. 2007 Jul;43(10):1564-73. Epub 2007 May 22. Review.

PMID:
17521904
11.

Proteasome as an emerging therapeutic target in cancer.

Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, Jakob C, Sezer O.

Curr Pharm Des. 2007;13(5):471-85. Review.

PMID:
17348844
12.

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.

Jakob C, Egerer K, Liebisch P, Türkmen S, Zavrski I, Kuckelkorn U, Heider U, Kaiser M, Fleissner C, Sterz J, Kleeberg L, Feist E, Burmester GR, Kloetzel PM, Sezer O.

Blood. 2007 Mar 1;109(5):2100-5. Epub 2006 Nov 9.

13.

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.

Heider U, Kaiser M, Müller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O.

Eur J Haematol. 2006 Sep;77(3):233-8.

PMID:
16923110
14.

Angiogenesis in multiple myeloma.

Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M, Sezer O.

Eur J Cancer. 2006 Jul;42(11):1581-90. Epub 2006 Jun 23. Review.

PMID:
16797965
15.

Bone markers in multiple myeloma.

Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, Sezer O.

Eur J Cancer. 2006 Jul;42(11):1544-53. Epub 2006 Jun 9. Review.

PMID:
16765040
16.

The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.

Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U.

Haematologica. 2006 Feb;91(2):248-51.

17.

Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours.

Davies AH, Larsson G, Ardill J, Friend E, Jones L, Falconi M, Bettini R, Koller M, Sezer O, Fleissner C, Taal B, Blazeby JM, Ramage JK; EORTC Quality of Life Group.

Eur J Cancer. 2006 Mar;42(4):477-84. Epub 2006 Jan 18.

PMID:
16412628
18.

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.

Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O.

Eur J Haematol. 2006 Jan;76(1):42-50.

PMID:
16343270
19.

Proteasome: an emerging target for cancer therapy.

Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K, Sezer O.

Anticancer Drugs. 2005 Jun;16(5):475-81. Review.

PMID:
15846112
20.

Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.

Heider U, Zavrski I, Jakob C, Bängeroth K, Fleissner C, Langelotz C, Possinger K, Hofbauer LC, Viereck V, Sezer O.

J Cancer Res Clin Oncol. 2004 Aug;130(8):469-74. Epub 2004 Jun 15.

PMID:
15205949
21.

Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.

Heider U, Fleissner C, Zavrski I, Jakob C, Dietzel T, Eucker J, Ockenga J, Possinger K, Sezer O.

Eur J Haematol. 2004 Jan;72(1):64-6.

PMID:
14962266
22.

Identification and clinical relevance of receptor activator of nuclear factor kappaB ligand expression of myeloma cells.

Heider U, Zavrski I, Jakob C, Fleissner C, Sezer O.

Cancer Res. 2004 Jan 15;64(2):773-4; author reply 774-5. No abstract available.

23.

Bisphosphonates in early multiple myeloma.

Sezer O, Jakob C, Zavrski I, Heider U, Fleissner C, Freund M.

Eur J Haematol. 2003 Sep;71(3):231-2. No abstract available.

PMID:
12930327
24.
25.

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.

Zavrski I, Naujokat C, Niemöller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K, Sezer O.

J Cancer Res Clin Oncol. 2003 Jul;129(7):383-91. Epub 2003 Jul 8.

PMID:
12851815
26.

Circulating hepatocyte growth factor levels in multiple myeloma.

Jakob C, Fleissner C, Zavrski I, Heider U, Possinger K, Sezer O.

Br J Haematol. 2003 May;121(3):532. No abstract available.

PMID:
12716383
27.

Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.

Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, Possinger K, Hofbauer LC, Sezer O.

Clin Cancer Res. 2003 Apr;9(4):1436-40.

28.

Intrinsic expression of drug resistance-associated factors in meningiomas.

Tews DS, Fleissner C, Tiziani B, Gaumann AK.

Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):242-9.

PMID:
11556752

Supplemental Content

Loading ...
Support Center